Patents by Inventor Magoichi Sako
Magoichi Sako has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230193350Abstract: The present invention provides: a method for identifying a blood cancer patient who may benefit from a monotherapy using a drug comprising a DNA methyl transferase inhibitor and a combination therapy using the aforesaid drug together with another epigenetic controller; a pharmaceutical composition to be used in treating a patient who has been identified or selected by the method; and a kit for identifying such a patient. More particularly, the aforesaid method comprises a step for measuring the expression amount of DUSP5 in a sample obtained from a blood cancer patient. When the expression amount measured in this step is lower than a reference expression amount of DUSP5, then the patient is identified or selected as a blood cancer patient who may benefit from a treatment using the drug comprising a DNA methyl transferase inhibitor.Type: ApplicationFiled: June 11, 2021Publication date: June 22, 2023Inventors: Yuki Kurahashi, Magoichi Sako, Hiroo Wakita, Shinya Kimura, Tatsuro Watanabe, Yuta Yamamoto
-
Publication number: 20220347197Abstract: [Problems] The object is to provide a compound as a therapeutic or prophylactic agent for TKI-resistant CML to replace the injection “Dacogen®” which has been clinically used as a therapeutic agent for high-risk myelodysplastic syndrome and acute myeloid leukemia. The said compound has remarkable stability against cytidine deaminase, a hydrolytic enzyme, and is absorbed in vivo even by oral administration, incorporated into the biosynthesis route of nucleic acid, and exhibits the effect of inhibiting DNA methyltransferase (DNMT).Type: ApplicationFiled: September 24, 2020Publication date: November 3, 2022Inventors: Magoichi Sako, Yuki Kurahashi, Shinya Kimura, Tatsuro Watanabe, Hiroshi Ureshino, Kazuharu Kamachi
-
Publication number: 20200123190Abstract: To provide, in place of injected agents (nucleoside-based anticancer agents or antivirus agents) clinically used as therapeutic drugs for cancer or virus infections, a medicine that has high stability with respect to various hydrolytic metabolic enzymes, is absorbed into the body even by oral administration, and exhibits a cytocidal effect by being incorporated into a DNA and RNA biosynthetic route and inhibiting the modification and extension of DNA and RNA or inhibiting reverse transcriptases or inhibiting protein synthesis. The aforementioned problem is solved by a novel compound represented by formula (I). (In the formula, D is the 5?-position moiety of a nucleoside-based anticancer agent or an antivirus agent, and R1 and R2 are each a benzyl group that may have the same substituent or different substituents.Type: ApplicationFiled: April 24, 2018Publication date: April 23, 2020Inventor: Magoichi Sako
-
Patent number: 10227374Abstract: The present invention relates to a prodrug of 5-azacytidine or 2?-deoxy-5-azacytidine having remarkable stability against cytidine deaminase, a metabolic hydrolyzing enzyme in replacement of current injections (5-azacytidine or 2?-deoxy-5-azacytidine) which are clinically used as therapeutic agents for various myelomas including myelodysplastic syndrome. The present invention provides a compound represented by formula (1), or salt thereof, wherein, R is OR3 or a hydrogen atom, R1, R2, and R3 are each independently hydrogen atom or silyl group represented by formula (2): wherein, R4, R5, and R6 are each independently alkyl group which may have a substituent, aryl group which may have a substituent, or arylalkyl group which may have a substituent, with the provision that R1, R2, and R3 are not hydrogen atom simultaneously.Type: GrantFiled: February 22, 2018Date of Patent: March 12, 2019Assignee: Ohara Pharmaceutical Co., Ltd.Inventors: Magoichi Sako, Shinpei Sugiyama
-
Publication number: 20180179246Abstract: The present invention relates to a prodrug of 5-azacytidine or 2?-deoxy-5-azacytidine having remarkable stability against cytidine deaminase, a metabolic hydrolyzing enzyme in replacement of current injections (5-azacytidine or 2?-deoxy-5-azacytidine) which are clinically used as therapeutic agents for various myelomas including myelodysplastic syndrome. The present invention provides a compound represented by formula (1), or salt thereof, wherein, R is OR3 or a hydrogen atom, R1, R2, and R3 are each independently hydrogen atom or silyl group represented by formula (2): wherein, R4, R5, and R6 are each independently alkyl group which may have a substituent, aryl group which may have a substituent, or arylalkyl group which may have a substituent, with the provision that R1, R2, and R3 are not hydrogen atom simultaneously.Type: ApplicationFiled: February 22, 2018Publication date: June 28, 2018Applicant: OHARA PHARMACEUTICAL CO., LTD.Inventors: Magoichi Sako, Shinpei SUGIYAMA
-
Patent number: 9901641Abstract: The present invention relates to a prodrug of 5-azacytidine or 2?-deoxy-5-azacytidine having remarkable stability against cytidine deaminase, a metabolic hydrolyzing enzyme in replacement of current injections (5-azacytidine or 2?-deoxy-5-azacytidine) which are clinically used as therapeutic agents for various myelomas including myelodysplastic syndrome. The present invention provides a compound represented by formula (1), or salt thereof, wherein, R is OR3 or a hydrogen atom, R1, R2, and R3 are each independently hydrogen atom or silyl group represented by formula (2): wherein, R1, R5, and R6 are each independently alkyl group which may have a substituent, aryl group which may have a substituent, or arylalkyl group which may have a substituent, with the provision that R1, R2, and R3 are not hydrogen atom simultaneously.Type: GrantFiled: November 18, 2016Date of Patent: February 27, 2018Assignee: Ohara Pharmaceutical Co., Ltd.Inventors: Magoichi Sako, Shinpei Sugiyama
-
Publication number: 20170304337Abstract: The present invention relates to a prodrug of 5-azacytidine or 2?-deoxy-5-azacytidine having remarkable stability against cytidine deaminase, a metabolic hydrolyzing enzyme in replacement of current injections (5-azacytidine or 2?-deoxy-5-azacytidine) which are clinically used as therapeutic agents for various myelomas including myelodysplastic syndrome. The present invention provides a compound represented by formula (1), or salt thereof, wherein, R is OR3 or a hydrogen atom, R1, R2, and R3 are each independently hydrogen atom or silyl group represented by formula (2): wherein, R1, R5, and R6 are each independently alkyl group which may have a substituent, aryl group which may have a substituent, or arylalkyl group which may have a substituent, with the provision that R1, R2, and R3 are not hydrogen atom simultaneously.Type: ApplicationFiled: November 18, 2016Publication date: October 26, 2017Applicant: OHARA PHARMACEUTICAL CO., LTD.Inventors: Magoichi SAKO, Shinpei SUGIYAMA
-
Patent number: 9670238Abstract: The present invention relates to a novel compound represented by formula (1), or salt thereof, wherein R is hydroxy group or hydrogen atom; R1 and R2 are the same or different, and are each independently benzyl group which may have a substituent. The present invention provides therapeutically agents, which have remarkable stability against cytidine deaminase, a metabolic enzyme, can be absorbed in vivo by oral administration and inhibit protein synthesis by being incorporated easily into nucleic acid bio-synthesis in vivo for replacing injection agent (5-azacytidine or 2?-deoxy-5-azacytidine) used in clinic for treating myeloma.Type: GrantFiled: November 18, 2016Date of Patent: June 6, 2017Assignee: Ohara Pharmaceutical Co., Ltd.Inventors: Magoichi Sako, Xiong Luo
-
Publication number: 20170152275Abstract: The present invention relates to a novel compound represented by formula (1), or salt thereof, wherein R is hydroxy group or hydrogen atom; R1 and R2 are the same or different, and are each independently benzyl group which may have a substituent. The present invention provides therapeutically agents, which have remarkable stability against cytidine deaminase, a metabolic enzyme, can be absorbed in vivo by oral administration and inhibit protein synthesis by being incorporated easily into nucleic acid bio-synthesis in vivo for replacing injection agent (5-azacytidine or 2?-deoxy-5-azacytidine) used in clinic for treating myeloma.Type: ApplicationFiled: November 18, 2016Publication date: June 1, 2017Applicant: OHARA PHARMACEUTICAL CO., LTD.Inventors: MAGOICHI SAKO, XIONG LUO
-
Patent number: 4490292Abstract: Novel 1,5-benzothiazepine derivatives having the formula; ##STR1## (wherein R.sub.1, R.sub.2 and R.sub.3 each denotes hydrogen, a halogen, a lower alkyl group, a lower alkoxy group or a hydroxy group; R.sub.4 denotes a lower alkyl group, an allyl group, a lower alkoxyalkyl group, a lower alkyl group substituted with a hydroxy group or a halogen, a lower alkylaminoalkyl group or a morpholino lower alkyl group; X denotes a halogen or hydrogen) are produced from corresponding 1,4-benzothiazine by a ring expansion reaction with trimethylhalosilane, hydrogen peroxide and water. The derivatives have analgesic, antipyretic and antiarrythmic activities.Type: GrantFiled: October 7, 1983Date of Patent: December 25, 1984Assignee: Hamari Chemicals, Ltd.Inventors: Yoshifumi Maki, Magoichi Sako, Naomichi Mitsumori, Sadayuki Maeda, Masahiro Takaya